Key facts
- It has raised $11.4M; the latest was Angel (individual) ($8.0M) in Jan 2026.
- Notable investors include Joseph White, Andrew Roosevelt, Brandon Salomon, Cenk Bekmezçi, Elvis Ndansi — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Carna Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Carna Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Carna Health
Developer of an advanced kidney health technology platform intended to help in the early detection and management of kidney disease. The company's platform integrates with existing healthcare systems and provides crucial health metrics such as creatinine, estimated glomerular filtration rate (eGFR), and urine albumin to creatinine ratio (uACR) from just a few drops of blood, urine, and vital signs, enabling patients and healthcare professionals to ensure a proactive, smooth and personalized healthcare journey.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 29
- Website
- carna.health/
- Ownership
- Privately Held (backing)
Carna Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Carna Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Carna Health in its N-PORT filings yet. We sweep new filings monthly.